NEWS
Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14
Voyager Therapeutics (Nasdaq: VYGR) has announced a new license agreement with Novartis AG (NYSE: NVS) for a novel capsid from Voyager's TRACER™ capsid discovery platform. The capsid will be used in a gene therapy program targeting an undisclosed rare neurologic disease. This agreement expands Voyager's partnered portfolio of TRACER-enabled gene therapies to 14 programs.
Key financial terms include:
$15 million upfront payment to Voyager
Up to $305 million in potential milestone payments
Tiered mid- to high-single digit royalties on potential products
This marks the fifth gene therapy program in collaboration with Novartis, including Huntington's disease, spinal muscular atrophy, and three undisclosed indications.
Key financial terms include:
$15 million upfront payment to Voyager
Up to $305 million in potential milestone payments
Tiered mid- to high-single digit royalties on potential products
This marks the fifth gene therapy program in collaboration with Novartis, including Huntington's disease, spinal muscular atrophy, and three undisclosed indications.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2493Followers
107Following
27KVisitors
Follow